Conference Call │ FY/21 Results
Bad Homburg, 22 February 2022
Safe Harbor Statement
This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.
Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.
FY/21 Results, 22 February 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 2 |
Agenda
01
Key messages
02 | 03 | 04 | ||
Strategic update | Financial review | Outlook FY/22 | ||
FY/21 | ||||
FY/21 Results, 22 February 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 3 |
Our Purpose and Mission
Ever better medicine for ever
more people
We improve people's lives by providing high
quality and affordable health care
FY/21 Results, 22 February 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 4 |
Key Messages
2021
Good close to the year; delivered on improved FY/21 guidance
Dividend to increase to €0.92 per share - scrip dividend proposed; choice to re-invest dividend into FRE
2022
Targets return to earnings | Continued progress |
growth | back to normal operations |
expected | |
Transformation program | Ongoing recovery of |
Vision 2026 initiated for | business expected |
continued success | |
Mid-term
Medium-term growth targets confirmed and specified
Strategic roadmap:
Significant value creation
expected based on
new strategic imperatives
FY/21 Results, 22 February 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 22 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 February 2022 06:30:07 UTC.